Thesis (M. P. H.)--University of Hong Kong, 2007.

Thesis (M. P. H.)--University of Hong Kong, 2007. / Also available in print.

Thesis (M.S.)--Rochester Institute of Technology, 2008. / Typescript. Includes bibliographical references (leaf 68).

"An inaugural dissertation, for the degree of Doctor of Medicine ... University of Pennsylvania, on the eighth day of June, 1803"--P. (iii). / "Errata."--P. [58]. Dedicated to Ashton Alexander, M.D., and John Parnham, M.D. Microform version available in the Readex Early American Imprints series.

"An inaugural dissertation, for the degree of Doctor of Medicine ... University of Pennsylvania, on the eighth day of June, 1803"--P. (iii). / Dedicated to Ashton Alexander, M.D., and John Parnham, M.D. "Errata."--P. [58]. Microform version available in the Readex Early American Imprints series.

Thesis (doctoral)--Stockholm University, 1994. / Includes bibliographical references.

Thesis (doctoral)--Stockholm University, 1996. / Includes bibliographical references.

Thesis (Ph.D.(Microbiology))--University of Pretoria, 2006. / Includes bibliographical references. Available on the Internet via the World Wide Web.

BACKGROUND: Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa. METHODS: We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products. RESULTS: Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its potential has been incompletely evaluated, considering the overall experience and recent improvement of immunotherapy. Development and use of heterologous serum derivatives could protect people exposed to Ebola viruses with reasonable cost and logistics. CONCLUSION: Hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as treatment for exposure to the Ebola virus.

In the first half of 1955 an unusual infective disease appeared in my practice, which is centred on Dalston, a village which lies 4½ miles south-west of Carlisle, in the valley of the River Caldew. The condition became prevalent in February and March and affected a considerable number of my patients; there were no fatalities but the disease was the cause of much disability and loss of working time. The disease appeared to be infectious, and the illness was characterised by acute myalgia, disturbances of the reticulo endothelial system and central nervous system, and psychogenic sequelae which, in some instances, persisted for many months. Relapses, with recrudescences of symptoms, occurred in a proportion of those infected; in sane cases, several relapses occurred over a period of months, symptoms being minimal or absent between the recurrences. The clinical picture that emerged was one with which I was not familiar. At an early stage in the epidemic I considered the condition to be most like glandular fever, and therefore sent serum samples and blood films to the Pathological Laboratory of the Cumberland Infirmary for Paul Bunnell screening and examination of the films for the picture seen in glandular fever.